The preliminary top line results showed that CBD 100mg had a statistically significant advantage over placebo, with a p-value of 0.04. A small p-value (typically ≤ 0.05) indicates strong evidence against the null hypothesis, so you can basically rule out the null hypothesis. The trial assessed the efficacy of a uniquely developed Schedule 3 (pharmacist only) OTC CBD formulation on symptoms associated with insomnia in 208 participants over eight weeks. The study design randomised patients to receive daily doses of double-blind study medication of either CBD 50mg, CBD 100mg, or placebo for the eight-week period. The primary endpoint compares Insomnia Severity Inventory (ISI) scores for each dose compared to placebo. The ISI is a patient questionnaire completed at baseline (before study medication) then at week 4 and week 8. The primary endpoint analysis on the population showed no statistically significant difference between either CBD dose compared to placebo when tested at the 0.025 statistical significance level.
Source: Stockhead